MBX Biosciences Inc
MBXHealthcare|Biotechnology|USA
$61.05
-4.69 (-7.13%)
Tangible Book
$9.20
Upcoming Data Readouts (3)
Oct 2026
Est. completion
P1Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
NCT07142707n=124
May 2027
Est. completion
P2Hypoparathyroidism
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
NCT06531941n=60
Jan 2028
Est. completion
P3Hypoparathyroidism
A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism
NCT07699471n=160